Munchkin U.S. FDA process on hold

The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin's Grass Fed(TM) infant formula in the U.S. has been put on hold. Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S. "Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed(TM) is sold the relationship continues with business as usual," says Synlait CEO, Leon Clement. The development will not have a material impact on Synlait's forecast infant formula volumes. End CA:00334649 For:SML Type:GENERAL Time:2019-05-16 13:43:36